Search Results
Your search for this matches 25286 pages
Showing 6601 - 6650Expert Point of View: Steven J. Isakoff, MD, PhD
Steven J. Isakoff, MD, PhD, Director of Breast Cancer Clinical Research at Massachusetts General Hospital, Boston, found the TAMARISK study “interesting.” “Looking at genomic profiles of uterine cancer in both tamoxifen-associated uterine cancer, the researchers found a lower frequency of PIK3...
PI3K Pathway Activation May Underlie Tamoxifen-Associated Uterine Cancer
Even though it is infrequent, uterine cancer can develop in patients treated with tamoxifen. A study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) suggests that the mechanism by which uterine cancers develop is tamoxifen-induced PI3K pathway activation.1 Patients treated with...
Study Finds Guideline-Concordant Cervical Cancer Screening Dropped From 2005 to 2019 Among Women in the United States
Rates of cervical cancer screening have dropped recently in the United States, with screening rates lowest among Asian and Hispanic women, as well as women who live in rural areas, are uninsured, or are sexual minorities, according to findings published by Ryan Suk, PhD, and colleagues in JAMA...
UICC to Launch 3-Year Campaign to Create More Equitable Access to Cancer Services
On February 4, 2022, the Union for International Cancer Control (UICC) will launch a new 3-year campaign for World Cancer Day that brings together individuals, organizations, and governments around the world in an effort to create awareness and help close the gap in cancer care. The campaign...
Interferon-Alfa vs Hydroxyurea in Previously Untreated Patients With Polycythemia Vera and Essential Thrombocythemia
In a phase III trial (MPD-RC 112) reported in the journal Blood, John Mascarenhas, MD, and colleagues found no difference in 12-month complete response rates between treatment with pegylated interferon-alfa vs hydroxyurea in previously untreated patients with high-risk polycythemia vera or...
Depression Screening and Behavioral Health Referrals for Patients With Newly Diagnosed Breast Cancer in the Community Oncology Setting
In a study reported in JAMA, Hahn et al found that a depression screening and intervention program resulted in a higher rate of referral to behavioral health services vs education alone among patients with newly diagnosed breast cancer at community oncology centers located in Southern California....
New Study Examines Genetic Effects on Genitourinary Toxicity in Patients With Prostate Cancer
Although radiation can be an effective therapy for prostate cancer, about one in six men will experience more frequent or painful urination as a lingering side effect. These disruptive genitourinary toxicities can occur whether the patient receives conventionally fractionated radiotherapy or...
Durvalumab/Tremelimumab With or Without Radiotherapy in Resistant NSCLC
In a recent phase II clinical trial, the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab curtailed tumor growth in some patients with non–small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent. The addition of radiation therapy to the...
Presurgical Chemosensitivity May Play a Role in Informing Postsurgical Treatment for Patients With Gastric Cancer
A study published by Deng et al in JAMA Network Open showed that chemotherapy after surgery for gastric adenocarcinoma was significantly associated with longer survival in patients with chemosensitive disease, but not in those with very sensitive or refractory disease. These findings suggest that...
Addition of Capecitabine to Taxane/Anthracycline Adjuvant Chemotherapy for Early Breast Cancer: 15-Year Overall Survival Results of the FinXX Trial
As reported in the Journal of Clinical Oncology by Heikki Joensuu, MD, and colleagues, 15-year overall survival results from the Finland Capecitabine Trial (FinXX) showed that the addition of capecitabine to taxane/anthracycline adjuvant chemotherapy was associated with improved overall survival...
Relatlimab Plus Nivolumab Improves PFS in Patients With Previously Untreated Metastatic or Unresectable Melanoma
On this episode, we’ll hear about a combination therapy that improved progression-free survival (PFS) in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with...
Expert Point of View: Anne Blaes, MD, MS, and Virginia Kaklamani, MD
Commenting on the update of RxPONDER presented at the 2021 San Antonio Breast Cancer Symposium were Anne Blaes, MD, MS, Associate Professor of Hematology/Oncology at the University of Minnesota and Co-Director of the Screening, Prevention, Etiology and Cancer Survivorship Program at the Masonic...
RxPONDER Update Explores Benefit of Chemotherapy in Subgroups
Updated results of the SWOG S1007 RxPONDER trial confirmed the key takeaway from the previous analysis: adjuvant chemotherapy benefits premenopausal women but not postmenopausal women with hormone receptor–positive, HER2-negative disease, one to three positive lymph nodes, and a 21-gene Oncotype DX ...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, called the results of the AGILE study “very promising.” He moderated a press briefing that featured the abstract at the American Society of Hematology (ASH) Annual Meeting & Exposition. “Patients with the...
Study Finds Improved 2-Year Survival Rate for Adult Patients With Relapsed Philadelphia Chromosome–Positive ALL After Allogeneic Hematopoietic Cell Transplantation Over 20 Years
A retrospective, registry-based multicenter study by Bazarbachi et al published in Clinical Cancer Research evaluated clinical outcomes in patients with relapsed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) after allogeneic hematopoietic cell transplantation over a...
AGILE Study: Addition of Ivosidenib to Azacitidine Triples Median Overall Survival in Difficult-to-Treat AML Population
In patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who were ineligible for intensive chemotherapy, the addition of the IDH1 inhibitor ivosidenib to azacitidine significantly improved survival vs azacitidine alone, according to data presented at the 2021 American...
Educational Intervention Increases Knowledge About Prostate Cancer and Intention to Screen Among High-Risk Patients
In a study published by Charnita Zeigler-Johnson, PhD, MPH, and colleagues in the Journal of Racial and Ethnic Health Disparities, gathering men at high risk for developing prostate cancer for discussion about prostate cancer or other health concerns increased their knowledge about prostate cancer...
New Research Aims to Uncover Cellular Source of Barrett’s Esophagus
Two recent studies correct a long-standing misconception about the origins of Barrett’s esophagus and, in doing so, may point to new avenues of treatment or prevention to lower the risk of esophageal cancer. The first study, published by Singh et al in the journal Gastroenterology, demonstrated...
Antibiotics After Endoprosthetic Reconstruction for Lower-Extremity Bone Tumors: Comparison of Two Intravenous Regimens
In a study reported in JAMA Oncology, researchers in the Prophylactic Antibiotic Regimens in Tumor Surgery Investigators group found that 5 days vs 1 day of postoperative intravenous antibiotic prophylaxis did not reduce the incidence of surgical site infection and was associated with more...
Role of Expression of ERV RNA in Prostate Cancer
A molecular feature in prostate cancer called endogenous retroviral (ERV) RNA has been found to have prognostic value and also distinguish differences between prostate tumors in men of African and European or Middle Eastern ancestry, according to a study published by Kumar et al in the journal...
Global Burden of Cancer From 2010 to 2019
In an analysis reported in JAMA Oncology, researchers in the Global Burden of Disease 2019 Cancer Collaboration found a global increase in new cases of cancer, cancer deaths, and cancer-related disability-adjusted life-years (DALYs) between 2010 and 2019, with aspects of cancer burden differing...
Report Describes Identification of a Novel Therapeutic Target for Multiple Myeloma
Proteasome inhibitors, the therapeutic backbone of current treatments for multiple myeloma, are effective in treating newly diagnosed disease, but resistance or intolerance to these molecules often develops, leading to relapse. While studying a neglected tropical disease, Buruli ulcer, researchers...
Meredith M. Regan, ScD, on Early Breast Cancer: Updated Results From the TEXT and SOFT Trials
Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discusses findings that point to the potential benefits of using adjuvant exemestane plus ovarian function suppression (OFS) to treat premenopausal women with hormone receptor–positive early breast cancer. This conclusion came after 13 years...
Association of Autoantibodies to Gastric Mucosa and Risk of Gastric Cancer
In a case-control study reported in JAMA Oncology, Minkyo Song, MD, PhD, and colleagues found that seropositivity for gastric antiparietal cell antibodies (APCAs) was associated with an increased risk of gastric cancer among younger Finnish women who were seronegative for antibodies to Helicobacter ...
ASTRO Issues Clinical Guideline on External-Beam Radiation Therapy for Primary Liver Cancers
A clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external-beam radiation therapy (EBRT). Evidence-based recommendations outline indications and optimal EBRT...
Expert Point of View: Ciara O’Sullivan, MB, BCh, BAO
Invited discussant Ciara O’Sullivan, MB, BCh, BAO, of Mayo Clinic, Rochester, Minnesota, commented on the DESTINY-Breast03 trial at the 2021 San Antonio Breast Cancer Symposium. “The treatment of HER2-positive disease is an evolving landscape, with eight approved agents. Despite this rapid...
Effect of Daily Sitting Time and Weekly Physical Activity on Cancer Survivorship
In a study reported in JAMA Oncology, Cao et al found that the combination of increased daily sitting time and low weekly leisure-time physical activity was associated with poorer overall and cancer-specific survival among U.S. cancer survivors. Study Details The study involved data from a...
Second-Line T-DXd Improves Progression-Free Survival Across HER2-Positive Metastatic Breast Cancer Subgroups
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) lengthened progression-free survival and improved objective response rate compared to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) after trastuzumab and taxane therapy in women with HER2-positive metastatic breast...
New Study Examines Septic Shock in Patients With Hematologic Malignancies
Research published by Manjappachar et al in JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies. They found that the mortality rate was 67.8% at 28 days, and only 19.4% of patients remained alive after 90 days. The...
Is There an Association Between Maternal Hormonal Contraception Use and Risk of CNS Tumors in Children?
In a Danish nationwide cohort study reported in JAMA, Hargreave et al found no association between maternal hormonal contraception use and risk of central nervous system (CNS) tumors in children. As stated by the investigators, “The incidence of CNS tumors in children appears to be increasing, yet...
Palliative Care Use Among Commercially Insured U.S. Patients With Metastatic Cancer: 2001–2016
In a study reported in JCO Oncology Practice, Ferrario et al found that while use of palliative care among commercially insured patients aged 25 to 64 years in the United States with metastatic cancer has increased since 2001, use remained at 40% among patients with very poor–prognosis cancers in...
Anil Aktas-Samur, PhD, on Identifying Low-Risk Smoldering Multiple Myeloma
Anil Aktas-Samur, PhD, of Dana-Farber Cancer Institute, discusses study findings on the genomic characterization of non-progressor smoldering multiple myeloma, results that may provide a molecular definition of the disease as well as its risk-driving features. Combining this low-risk model with...
Role of Radiologist Experience and Fatigue Level in Recommending Additional Imaging for Patients Undergoing Breast Cancer Screening
Less experienced radiologists are more likely to recommend additional imaging for women undergoing breast cancer screening when they read digital breast tomosynthesis (DBT) images later in the day, according to a new study published by Bernstein et al in the journal Radiology. The results highlight ...
Study Uses Data From a Nationally Representative Colonoscopy Registry to Gather Information on Early-Onset Colorectal Precancerous Lesions
In a study published in the journal Gastroenterology, Trivedi et al described an increase in early-onset colorectal cancer and precancerous polyps, based on a large, nationally representative study of patients younger than 50 who underwent colonoscopy. It was the first large-scale study to look at...
Incidence of Chronic Graft-vs-Host Disease: Effect of Depleting Naive T Cells From Peripheral Blood Stem Cell Allografts in Patients With Leukemia
Although allogeneic hematopoietic cell transplantation can result in a cure for patients with advanced hematologic malignancies, studies show chronic graft-vs-host disease occurs in 30% to 60% of patients receiving unmanipulated grafts, often requires prolonged immunosuppression, and may cause...
Addition of Abiraterone Acetate and Prednisolone With or Without Enzalutamide to ADT in High-Risk Nonmetastatic Prostate Cancer
In a meta-analysis of two STAMPEDE platform phase III trials reported in The Lancet, Gerhardt Attard, PhD, and colleagues found that the addition of abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy (ADT) was associated with improved metastasis-free...
Developing a Comprehensive System for Personalized Survivorship-Centered Care Plans
By 2040, the number of cancer survivors in the United States is expected to climb from 17 million today to 26.1 million, with most living 5 years or more after their diagnosis. However, many of these survivors will need ongoing monitoring for treatment-related side effects and cancer recurrence...
EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer
Use of the first investigational oral selective estrogen receptor degrader (SERD) elacestrant significantly reduced the risk of death or disease progression and lengthened progression-free survival compared with standard-of-care endocrine therapy with fulvestrant or an aromatase inhibitor in...
Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment
In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving active cancer treatment. Antibody levels prior to and...
Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
In a pooled analysis of individual patient data from trials in the U.S. Food and Drug Administration database reported in JAMA Oncology, Anscher et al found that patients with cancer receiving radiotherapy within 90 days prior to the start of immune checkpoint inhibitor treatment were not at...
Single-Cell Transcriptomic and Imaging Atlas of Colorectal Polyps Provides Insights for Cancer Surveillance
A team of researchers has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the disease. Their study, published by Chen et al in the journal Cell, describes findings using a single-cell transcriptomic and imaging...
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
On this episode, we’re discussing a phase III trial that showed improved progression-free survival with VEGFR2 inhibition in certain patients with thyroid cancer. Then, we’ll hear about a report on outcomes of breakthrough COVID-19 infection among fully vaccinated patients with cancer.
Does Geography Play a Role in Early-Onset Colorectal Cancer in Young Black Men?
Although the incidence and mortality rates in colorectal cancer have dropped by 3.6% each year from 2007 to 2016 for people aged 55 and older—mainly because of increased colorectal cancer screening, advances in therapy, and reductions in smoking—these rates have increased by 2% each year during the ...
Study Finds Depression Screening Improves Behavioral Care for Patients With Breast Cancer
Research published by Hahn et al in JAMA showed depression screening for patients with newly diagnosed breast cancer was highly effective at identifying patients in need of behavioral health care. The new screening initiative was subsequently and successfully built into the patient care and daily...
FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to 5 Months
On January 7, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Moderna COVID-19 vaccine to shorten the time between the completion of a primary series of the vaccine and a booster dose to at least 5 months for individuals aged 18 years and older....
Trends in Population-Level Stage Shift and Mortality Among U.S. Patients With NSCLC: 2006–2016
In a retrospective cohort study reported in JAMA Network Open, Raja Flores, MD, and colleagues found that a population-level shift to earlier-stage diagnosis has been accompanied by a reduction in population-level mortality during recent years in U.S. patients with non–small cell lung cancer...
Imaging Biomarker May Help to Risk-Stratify Patients With Head and Neck Cancer
A team of scientists has used artificial intelligence (AI) to identify which patients with certain head and neck cancers may benefit from reducing the intensity of treatments such as radiation therapy and chemotherapy. Their findings were published by Corredor et al in the Journal of the National...
Portable Prostate Cancer Screening Test May Help Reach Underserved Patients
A portable, rapid prostate cancer screening kit could provide early warning to populations with a higher incidence of prostate cancer and may particularly aid those with limited access to health care. The proof-of-concept test, described by Srinivasan et al in Current Research in Biotechnology, is...
Be Realistic About What Patients Can Expect After Prostate Cancer Treatment
More than 1 in 10 patients with localized prostate cancer experienced treatment-related regret, a study published in JAMA Oncology suggests. And the major driver of that regret seems to be a disconnect between patient expectations and outcomes.1 In an interview with The ASCO Post, the study’s lead...
Disconnect Between Expectations and Outcomes: Major Factor in Treatment-Related Regret Among Patients With Localized Prostate Cancer
“A disconnect between patient expectations and outcomes” is a major contributor to treatment-related regret among patients with localized prostate cancer, according to a study published in JAMA Oncology.1 The disconnect, “both as it relates to treatment efficacy and adverse effects, appears to...
